InflaRx NV (IFRX)
2.25
+0.09
(+4.17%)
USD |
NASDAQ |
Sep 02, 14:19
InflaRx Cash from Investing (Quarterly) : 14.90M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.90M |
| March 31, 2026 | 7.182M |
| September 30, 2025 | 2.788M |
| June 30, 2025 | -26.80M |
| March 31, 2025 | 18.58M |
| September 30, 2024 | 19.92M |
| June 30, 2024 | 6.215M |
| March 31, 2024 | 29.24M |
| December 31, 2023 | 3.294M |
| September 30, 2023 | 8.032M |
| June 30, 2023 | -26.51M |
| March 31, 2023 | -3.848M |
| December 31, 2022 | 2.077M |
| September 30, 2022 | 4.308M |
| June 30, 2022 | -16.35M |
| March 31, 2022 | 29.71M |
| December 31, 2021 | -38.76M |
| Date | Value |
|---|---|
| September 30, 2021 | 6.753M |
| June 30, 2021 | 3.606M |
| March 31, 2021 | -1.264M |
| December 31, 2020 | -8.675M |
| September 30, 2020 | 11.82M |
| June 30, 2020 | 25.32M |
| March 31, 2020 | -2.992M |
| December 31, 2019 | 25.69M |
| September 30, 2019 | -22.42M |
| June 30, 2019 | 19.55M |
| March 31, 2019 | -0.2975M |
| December 31, 2018 | 9.127M |
| September 30, 2018 | -112.61M |
| June 30, 2018 | -9.84M |
| March 31, 2018 | -0.1585M |
| December 31, 2017 | -0.0721M |
| September 30, 2017 | -0.0628M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| MediGene AG | -- |
| BioNTech SE | -118.82M |
| Immatics NV | -9.277M |
| Beam Therapeutics, Inc. | -9.875M |
| Kymera Therapeutics, Inc. | 20.04M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.937M |
| Cash from Financing (Quarterly) | 138.70M |
| Free Cash Flow | -32.78M |
| Free Cash Flow Per Share (Quarterly) | -0.0253 |
| Free Cash Flow to Equity (Quarterly) | -2.984M |
| Free Cash Flow to Firm (Quarterly) | -2.962M |
| Free Cash Flow Yield | -17.91% |